The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face ...
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
In a report released today, Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report). The company’s ...
Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...
Novo Nordisk on Wednesday said its new trial of its next-generation obesity drug candidate CagriSema will look at dose ...
Novo Nordisk reported turnover from obesity treatments soared by 57 per cent to 65.1 billion Danish kroner last year, largely ...
Novo Nordisk shares rose sharply after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients ...
Danish healthcare company Novo Nordisk A/S (NVO)reported Wednesday that its fiscal 2024 net profit climbed 21 percent to 100.9 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback